fluconazole has been researched along with Airflow Obstruction, Chronic in 3 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endogenous and stimulated endothelial release of EETs was assessed in 12 patients with COPD, 11 overweight smokers, and two matched control groups, using forearm plethysmography with intraarterial infusions of fluconazole, bradykinin, and the combination." | 5.24 | Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. ( Ament, Z; Cheriyan, J; Griffin, JL; Gutterman, DD; Lazaar, AL; Mayer, RJ; Newby, DE; Tal-Singer, R; Wilkinson, IB; Yang, L, 2017) |
| "Prior use of fluconazole, severe respiratory failure and hospitalization time are associated with IPA in patients with chronic pneumopathies with respiratory isolation of Aspergillus spp." | 1.38 | [Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp]. ( Casal, M; Castón, JJ; Linares, MJ; Rivero, A; Torre-Cisneros, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, L | 1 |
| Cheriyan, J | 1 |
| Gutterman, DD | 1 |
| Mayer, RJ | 1 |
| Ament, Z | 1 |
| Griffin, JL | 1 |
| Lazaar, AL | 1 |
| Newby, DE | 1 |
| Tal-Singer, R | 1 |
| Wilkinson, IB | 1 |
| Chandran, SK | 1 |
| Lyons, KM | 1 |
| Divi, V | 1 |
| Geyer, M | 1 |
| Sataloff, RT | 1 |
| Castón, JJ | 1 |
| Linares, MJ | 1 |
| Rivero, A | 1 |
| Casal, M | 1 |
| Torre-Cisneros, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 i[NCT01762774] | Phase 1 | 56 participants (Actual) | Interventional | 2013-01-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fluconazole and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
Topics: 8,11,14-Eicosatrienoic Acid; Adult; Aged; Blood Vessels; Bradykinin; Case-Control Studies; Cyclohexy | 2017 |
2 other studies available for fluconazole and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Fungal laryngitis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Antifungal Agents; Candidiasis; Disease Suscept | 2009 |
[Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp].
Topics: Aged; Aged, 80 and over; Antifungal Agents; Aspergillus; Asthma; Bacterial Infections; Carrier State | 2012 |